Allene M. Diaz sold $4.4M of IONS
director at IONIS PHARMACEUTICALS INC. 54,878 shares at an average of $79.35, traded Mar 3, 2026, filed Mar 5, 2026.
Score components
- +15RoleDirector
- +25Trade size$4.4M at market
- +20Share of holdings soldSold 94% of holdings
- +15Cluster10 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000874015-26-000136, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | MOption exercise Common Stock10b5-1 | +10,321 | $41.08 | $424k | 28,689 | Mar 5, 2026 |
| Mar 3, 2026 | MOption exercise Common Stock10b5-1 | +12,000 | $38.06 | $457k | 40,689 | Mar 5, 2026 |
| Mar 3, 2026 | MOption exercise Common Stock10b5-1 | +18,000 | $40.05 | $721k | 58,689 | Mar 5, 2026 |
| Mar 3, 2026 | SOpen-market sale Common Stock10b5-1 | -39,265 | $79.11 | $3.1M | 19,424 | Mar 5, 2026 |
| Mar 3, 2026 | SOpen-market sale Common Stock10b5-1 | -14,608 | $79.88 | $1.2M | 4,816 | Mar 5, 2026 |
| Mar 3, 2026 | SOpen-market sale Common Stock10b5-1 | -1,005 | $80.80 | $81k | 3,811 | Mar 5, 2026 |
| Mar 3, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -12,000 | $0.00 | $0 | 0 | Mar 5, 2026 |
| Mar 3, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -18,000 | $0.00 | $0 | 0 | Mar 5, 2026 |
| Mar 3, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -10,321 | $0.00 | $0 | 0 | Mar 5, 2026 |
Related signals
Other insiders at IONIS PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | IONIS PHARMACEUTICALS INC | Eugene Schneider EVP, Chf Clinical Develop Ofcr | $412k 5,812 shares | -8% | |
| 47Moderate | IONIS PHARMACEUTICALS INC | Elizabeth L Hougen EVP, Finance & CFO | $16M 225,220 shares | -73% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Kyle Jenne EVP, Chf GL Pdt Str Ofcr | $2.8M 37,277 shares | -76% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Brett P Monia Chief Executive Officer | $12M 160,773 shares | -44% | |
| 37Weak | IONIS PHARMACEUTICALS INC | Patrick R. O'Neil EVP CLO & General Counsel | $764k 10,148 shares | -14% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | C Frank Bennett EVP, Chief Scientific Officer | $6.7M 85,089 shares | -51% | |
| 18Weak | IONIS PHARMACEUTICALS INC | Joseph Baroldi EVP, Chief Business Officer | $531k 6,659 shares | -15% | |
| 30Weak | IONIS PHARMACEUTICALS INC | Shannon L. Devers EVP, Chief Human Resources Ofc | $1.6M 20,106 shares | -47% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Joseph Klein III director | $1.7M 21,332 shares | -66% | |
| 4Weak | IONIS PHARMACEUTICALS INC | Joseph Loscalzo director | $83k 1,032 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.